Key result
Sodium tanshinone IIA sulfonate significantly improved cardiac function and reduced scar size, myocardial necrosis, and inflammation in mice 28 days post-myocardial infarction.
Why the study?
Myocardial infarction leads to pathological cardiac remodeling and heart failure, and sodium tanshinone IIA sulfonate shows therapeutic potential, but its role in post-MI ventricular remodeling required exploration.
Does sodium tanshinone IIA sulfonate improve adverse ventricular remodeling post-MI in a mouse model?
RCT
Randomly divided
Does sodium tanshinone IIA sulfonate improve adverse ventricular remodeling post-MI in a mouse model?
In a mouse model of MI, sodium tanshinone IIA sulfonate improved pathological cardiac remodeling by reducing necrosis, modulating inflammation, and promoting angiogenesis.
No takes yet. Share an insight, caveat, or question.
Should not change post-MI care; hypothesis-generating in mice and requires human trials.
Zhang et al. (2021) conducted an RCT in Myocardial infarction. Sodium tanshinone IIA sulfonate (STS) vs. Normal saline (NS) and sham was evaluated on Cardiac function, scar size, and myocardial fibrosis-associated markers. Sodium tanshinone IIA sulfonate significantly improved cardiac function and reduced scar size, myocardial necrosis, and inflammation in mice 28 days post-myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: